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Abstract
A preclinical model of troponin I-induced myocarditis (AM) revealed a prominent role of the immunoproteasome (ip), the 
main immune cell-resident proteasome isoform, in heart-directed autoimmunity. Viral infection of the heart is a known trigger 
of cardiac autoimmunity, with the ip enhancing systemic inflammatory responses after infection with a cardiotropic cox-
sackievirusB3 (CV). Here, we used ip-deficient A/J-LMP7−/− mice to investigate the role of ip-mediated effects on adaptive 
immunity in CV-triggered myocarditis and found no alteration of the inflammatory heart tissue damage or cardiac function 
in comparison to wild-type controls. Aiming to define the impact of the systemic inflammatory storm under the control of ip 
proteolysis during CV infection, we targeted the ip in A/J mice with the inhibitor ONX 0914 after the first cycle of infection, 
when systemic inflammation has set in, well before cardiac inflammation. During established acute myocarditis, the ONX 
0914 treatment group had the same reduction in cardiac output as the controls, with inflammatory responses in heart tissue 
being unaffected by the compound. Based on these findings and with regard to the known anti-inflammatory role of ONX 
0914 in CV infection, we conclude that the efficacy of ip inhibitors for CV-triggered myocarditis in A/J mice relies on their 
immunomodulatory effects on the systemic inflammatory reaction.
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Introduction
Enteroviruses (EV), members of the Picornaviridae fam-
ily, comprise a genus of positive-sense single-stranded 
RNA viruses that are implicated in a broad range of clini-
cal manifestations. For EV-associated health problems 
such as pancreatic failure, cardiovascular collapse, hepati-
tis and encephalitis, neither vaccination nor effective anti-
viral drugs are available [50, 52]. The pressure to develop 
safe and effective anti-EV drugs is acute, particularly for 
newborn infants and young children, who, during periods 
of high EV prevalence, are at risk for life-threatening sep-
tic syndromes. CoxsackievirusB3 (CV), belonging to the 
genus EV, is a clinically relevant and well-studied human 
pathogen that, in addition to an initial wave of systemic 
inflammatory responses, can cause a second wave of viral 
injury targeting the heart and leading to myocarditis with 
a potentially severe outcome. CV is a pathogen known to 
cause viral myocarditis in North America and Europe [18]. 
Infection of laboratory mouse strains with cardiotropic CV 
reflects the disease in man, including its biphasic course, 
to a remarkable extent, with evidence for a contribution 
of specific viral proteins, such as the viral protease 2A, 
in triggering cytoskeletal protein disruption and shutting 
down Cap-dependent protein translation in cardiomyocytes 
[4, 53]. CV exploits the cellular machinery to promote 
its own replication and thereby disturbs the integrity of 
infected cells in the heart.
In addition to direct virus-triggered pathology, cardiac 
dysfunction in viral myocarditis involves inflammatory 
processes, initially induced by virus replication interme-
diates activating intracellular pattern recognition recep-
tors (PRR), which help the host prevent uncontrolled virus 
replication and tissue damage [3, 45, 51]. Concomitant to 
these innate immune responses, classical pro-inflamma-
tory immune action follows, comprising the infiltration 
of NK cells and monocytes/macrophages, as well as to a 
minor extent B and T cells, all assumed to dampen and 
control virus-triggered pathology [27]. Although there 
is considerable evidence for a protective contribution of 
such an immune reaction, there is also consensus that the 
inflammatory process triggered by virus infection of heart 
tissue actually drives cardiac damage responses, leading 
to disarranged cardiac cells, fibrotic tissue repair and ven-
tricular dilation [14]. It was once thought that the presence 
or the persistence of virus genomes in the human heart 
determines disease outcome in viral myocarditis, but that 
idea has since been discarded [19]. In fact, the abundance 
of infiltrating leukocytes is an independent risk factor for 
the pathologic progression of acute myocarditis into long-
term cardiac dysfunction [30]. The majority of the accu-
mulated leukocytes in inflamed heart tissue of CV-infected 
mice are  CD11b+ monocytes and macrophages [35, 40], 
with infiltration of these immune cells being driven by 
respective chemotactic cytokines [2]. Others and we dem-
onstrated that particularly those infiltrating myeloid cells 
contribute to acute and chronic functional impairment in 
inflammatory heart disease [24, 35]. Another explana-
tion for how virus-induced inflammation results in ongo-
ing inflammatory responses in heart tissue is the fact that 
acute viral myocarditis can trigger a loss of self-tolerance 
against cardiac proteins, leading to heart-directed auto-
immunity [41]. The underlying immune pathways can be 
investigated in mouse models of experimental autoimmune 
myocarditis (AM), where administration of cardiac myo-
sin, troponin I or their pathogenic epitopes, in combina-
tion with an adjuvant, induces a cardiac damage response, 
mimicking central aspects of inflammatory cardiomyopa-
thy in humans [16, 20]. Interestingly, in AM mouse mod-
els, infiltrating  CD11b+ monocytes and macrophages, or 
the chemotactic molecules produced by these and other 
immune cells, are also central for disease manifestation 
[33, 35, 54]. Human monocytes, the main producers of 
pro-inflammatory cytokines, not only govern inflammation 
and pro-fibrotic tissue injury in AM, they can also guide 
the expansion of autoreactive  CD4+ T cells and their dif-
ferentiation into Th17 cells, the later promoting cardiac 
autoimmunity [5, 39].
We have previously demonstrated that the immunopro-
teasome (ip), the most abundant proteasome isoform in 
immune cells, regulates the production of pro-inflammatory 
and chemotactic cytokines by monocytes/macrophages, the 
activation and differentiation of autoreactive  CD4+ T cells, 
as well as cardiac inflammatory responses, both in viral 
myocarditis and in troponin I-induced AM [2, 12]. The ip is 
a multi-subunit, barrel-shaped proteolytic complex, where 
a gated pore within the two outer alpha rings of the com-
plex controls the accessibility of degradation-prone protein 
substrates to the catalytic center in the interior of the two-
fold symmetric chamber. The three β-subunits, β1i (LMP2), 
β2i (Mecl-1) and β5i (LMP7) [1], in the inner cavity of the 
complex execute peptide hydrolysis, with each subunit hav-
ing a cleavage site preference for specific amino acids. Par-
ticularly the cleavage-site usage [36] and to a lesser extent 
the qualitative cleavage site properties [29] demarcate this 
proteasome isoform from its standard proteasome coun-
terpart, the main isoform found in somatic cells. Both the 
spatial heterogeneity of proteasome isoforms in distinct 
cellular compartments and the pro-inflammatory function 
of the ip in preclinical models of autoimmunity promoted 
research activities aiming at precisely targeting of the pro-
teasome isoform in immune cells [7, 22, 37, 47, 49]. ONX 
0914, a well-studied irreversible epoxyketone inhibitor that 
blocks virtually all ip subunits to a varying degree [8, 40], 
and the LMP7-selective dipeptide inhibitor DPLG3 [47] are 
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examples of such accomplishments and both ONX 0914 and 
DPLG3 can suppress adverse inflammatory tissue damage 
of the heart [2, 12, 49]. The portfolio of protective features, 
accomplished by selective inhibition of the ip, encompasses 
altered T cell activation/differentiation, promoting the sur-
vival of fewer Th17 and more regulatory T cells [12, 26, 49], 
and elevated expression levels of inhibitory immune check-
point molecules, such as PD-1 [12, 49]. Undisputedly, these 
aspects are protective in instances like cardiac autoimmunity 
or allograft rejection after heart transplantation.
However, the contribution of such processes of adaptive 
immunity to cardiac inflammation, as rapidly evolving as 
they are after invasion of cardiotropic CV to the heart, is 
unclear. Our previous study investigated CV myocarditis in 
A/J mice and we demonstrated that ONX 0914 exerted rapid 
effects, yielding a profound suppression of the early sys-
temic inflammatory cytokine response that we attributed to 
impaired signaling processes in myeloid-derived monocytes/
macrophages [2]. Whether, however, the improved cardiac 
output and attenuated myocardial injury that we found in the 
ONX 0914 group reflects a systemic anti-inflammatory or 
a more cardio-selective reaction is unclear. Here, we tack-
led the question of whether the ip can specifically influence 
viral myocarditis in A/J mice. This would commence in a 
period after the first wave of viral infection has damaged the 
pancreas and liver, thereby establishing systemic inflamma-
tion and setting up replication of the virus in the heart. We 
used A/J-LMP7−/− mice to discriminate processes of acute 
systemic inflammatory responses, such as PRR-triggered 
pro-inflammatory cytokine production in monocytes/mac-
rophages, known to be unaffected by LMP7 ablation [11, 
15, 37], from those of cardiodepressive adverse immune 
responses present in  LMP7−/− mice [7, 9, 12, 37]. In an 
alternative approach, we selectively inhibited the ip with 




Original mating pairs of the A/J wild-type mouse 
strain were purchased from Harlan Winkelmann (A/J). 
 LMP7−/− mice, originally generated by Fehling et al. [17] 
and provided to our group by the Steinhoff laboratory on 
a C57BL/6 background, were backcrossed into an A/J 
background for at least seven generations, using speed 
congenics. The offspring of heterozygous A/J-LMP7−/+ 
breeding pairs generated  LMP7−/− and  LMP7+/+ wild-type 
littermate controls (F8). For ONX 0914 treatment in A/J 
mice, in the majority of experiments, larger cohorts of 
male A/J mice were purchased from Envigo and mice were 
allowed to settle for at least 1 week prior to virus inocula-
tion or ONX 0914 treatment. Male animals (− 8 weeks) 
were injected intraperitoneally (i.p.) with  104 PFU of a 
cardiotropic variant of CVB3 Nancy strain [31]. All mice 
were kept at the animal facilities of the Charité Univer-
sity Medical Center. For the therapeutic ONX 0914 treat-
ment, mice were injected subcutaneously with 10 mg/kg 
body weight (BW) ONX 0914 or the vehicle Captisol daily 
from days 3 to 7. On the final day of each infection study, 
after echocardiography, organs were collected for further 
analysis and immediately frozen in liquid nitrogen. Organs 
were stored at − 80 °C. Heart tissue was fixed in HistoFix 
(1xPBS, 4%  ROTI®Histofix) overnight and embedded in 
paraffin. To visualize cardiac infiltration, cross sections 
were stained with hematoxylin and eosin and judged by a 
pathologist as described elsewhere [45]. Whole blood was 
centrifuged at 4 °C and 10,000 rcf for 15 min to separate 
serum, which was then collected and stored at − 80 °C.
This study was carried out in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
Animals of the German Animal Welfare Act, which is based 
on the directive of the European Parliament and the Council 
of Europe Convention for the Protection of Vertebrate Ani-
mals used for Experimental and other Scientific Purposes 
(ETS123). This study was approved by the local authorities 
for animal welfare in Berlin (permit numbers: G0054/18, 
G 0274/13, G103/18). All efforts were made to minimize 
suffering.
Echocardiography
For echocardiography, mice were anesthetized with 1.5–2% 
isoflurane and kept warm on a heated platform. Temperature 
and ECG were monitored continuously. Cardiac function and 
morphology were assessed with a VisualSonics Vevo 3100 
High-Frequency Imaging System using a high-resolution 
(44 MHz) transducer. Standard imaging planes, M-mode, 
and functional calculations were obtained. For the paraster-
nal long axis LV trace, the average systolic or diastolic vol-
ume in B-Mode is based on the rotational volume of the LV 
trace at systole or diastole around the long axis of the spine. 
The parasternal long-axis view of the left ventricle (LV) 
was used to guide calculations of ventricular dimensions 
(M-mode), volumes (B mode; LV vol; d = LV trace end-dias-
tolic; LV vol; s = LV trace end-systolic; stroke volume using 
the formula  =  v; − v;) and left ventricular ejection fraction 
(B mode using the formula  = 100 × ( v; − v; v; )). M-mode 
echocardiographic images were recorded at the level of the 
papillary muscles from the parasternal short-axis view. All 
measurements were performed by the Animal Phenotyping 
Platform of the Max-Delbrück-Center for Molecular Medi-
cine in Berlin.
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Cell culture, isolation of immune cells from mouse 
tissue
For the analysis of bone marrow cells, flushed bone mar-
row was passed through 40 μm cell strainers, centrifuged, 
and resuspended with RPMI. Splenocytes were prepared by 
passing spleen tissue trough a 70 μm cell strainer (BD Bio-
sciences). After a wash step with 1 × PBS, RBC lysis was 
performed 2–3 times by incubating in 0.83% ammonium 
chloride  (NH4Cl) for 3–5 min at room temperature. Cells 
were recovered by centrifugation (10 min, 310g), re-sus-
pended in FACS buffer, and chilled on ice until flow cytom-
etry was carried out.
For heart tissue, after extraction of whole blood the heart 
was flushed with 15 mL PBS, removed and washed again 
in PBS. An amount of heart tissue defined by weight was 
minced in RPMI 1640 medium (Biochrom) containing 10% 
(v/v) fetal calf serum (FCS) (Biochrom), 1% (v/v) penicil-
lin/streptomycin (Pan Biotech), 30 mM HEPES, 0.1% (w/v) 
collagenase type 2 (Worthington) and 0.015% (w/v) DNase 
I (Sigma-Aldrich). Tissue digestion was carried out by incu-
bating at 37 °C for 30 min while shaking at 800 rpm. To 
ensure the cells did not clump together, 10 mM EDTA was 
added, the cells were washed with PBS, and were passed 
through a 70 μm cell strainer (BD Biosciences). Cells were 
recovered by centrifugation (10 min, 310g), re-suspended 
in FACS buffer, and chilled on ice until flow cytometry was 
performed.
Proteasome inhibitor ONX 0914
For subcutaneous administration in mice, ONX 0914 (Cay-
man Chemicals) was dissolved at a concentration of 1–2 mg/
mL in an aqueous solution of 1 mg/mL Captisol (Ligand 
Pharmaceuticals) and sodium citrate at a pH of 3.5. Aliquots 
of both ONX 0914 and Captisol were stored at − 20 °C.
Flow cytometry
Equal numbers of splenocytes or cells purified from 15 mg 
heart tissue were incubated (20 min at 4 °C) in FACS buffer 
(1xPBS, 2% FCS, 2 mM EDTA) containing an anti-mouse 
Fc receptor blocking reagent (1:50; Miltenyi Biotec). 
Afterwards, fluorochrome-conjugated antibodies against 
various surface markers were added and incubated for at 
least 20 min at 4 °C while protected from light. The fol-
lowing antibodies were purchased from BD Bioscience: 
CD8α (FITC; clone 53-6.7), B220 (PE; clone RA3-6B2), 
CD90.2/Thy-1.2 (PE; clone 53-2.1), TER-119 (PE; clone 
TER-119), CD11b (PE-CF594; clone M1/70), CD4 (V500; 
clone RM4-5), CD8α (Pacific Blue™; clone 53.6.7). CD49b 
(PE; clone DX5), CD44 (PE; clone IM7) and CD3 (APC; 
clone 2-C11) were purchased from eBioscience. CD45.2 
(Brilliant Violet 711™; clone 104), Ly6G (PerCP/Cy5.5; 
clone 1A8), Ly6C (Pacific Blue™; clone HK1.4), CD11c 
(Brilliant Violet 510™; clone N418), F4/80 (APC; clone 
BM8), CD3 (PerCP/Cy5.5; clone 145-2C11), B220 (FITC; 
clone RA3-6B2), CD19 (APC; clone 6D5) were purchased 
from BioLegend. After several wash steps with FACS buffer 
(centrifugation: 3 min at 300g), cells were re-suspended in 
150 μL of the fixable viability dye eFluor 780 (eBioscience), 
diluted 1:1.000 in PBS and incubated for 30 min on ice pro-
tected from light. After serial wash steps with PBS followed 
by fixation in FACSFix (1x PBS, 2% RothTMHistofix), cells 
were acquired on either a FACS Symphony flow cytometer 
(BD Biosciences). Data were analyzed using FlowJo v10.0 
software (Tree Star). To quantify total cell numbers in heart 
tissue, 123 count eBeads (eBioscience) were used accord-
ing to the manufacturer’s protocol. Reported numbers were 
normalized for the weight of total hearts yielding the number 
of cells per mg tissue. Monocytes were identified by positive 
gating for CD45, CD11b and exclusion of Ly6G, CD11c and 
F4/80-positive cells in addition to lineage negative staining 
(B220, CD90.2, CD49b and Ter-119) as recently described 
[23]. Expression of Ly6C was used to discriminate between 
patrolling and inflammatory monocytes.
RNA isolation and quantitative real‑time PCR (qPCR)
RNA was isolated using  TRIzol® (Ambion) method accord-
ing to the manufacturer’s instructions. Remaining DNA was 
removed by digestion with DNAse I (Invitrogen) at 37 °C 
for 15 min followed by enzyme deactivation at 65 °C for 
10 min. 250–1000 ng RNA were reverse transcribed with 
MLV Reverse Transcriptase (Promega) in combination 
with random hexamer primers (Roche).  TaqMan® PCR 
was performed using primers and probes of  TaqMan® gene 
expression assays (Life Technologies) as well as the fol-
lowing combinations of primers and probes: murine HPRT 
fw: 5′-ATC ATT ATG CCG AGG ATT TGG AA-3´, rev: 
5′-TTG AGC ACA CAG AGG GCC A-3′, probe: 5′FAM- 
TGG ACA GGA CTG AAA GAC TTG CTC GAG ATG 
-3′TAMRA; CV fw: 5′-CCC TGA ATG CGG CTA ATC 
C-3′, rev: 5′-ATT GTC ACC ATA AGC AGC CA-3′ probe: 
5′-FAM-TGC AGC GGA ACC G -MGB3′. qPCR was con-
ducted on a StepOnePlus™ real-time PCR system.  TaqMan® 
assays for HPRT served as endogenous controls and were 
used to calculate relative expression using the ΔC(t) or 
ΔΔC(t) method.
Quantification of infectious viral particles
Plaque assays were performed on sub-confluent monolayers 
of green monkey kidney cells incubated with serial tenfold 
dilutions of cell culture supernatant or supernatant from 
homogenized mouse tissue. After incubation at 37 °C for 
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1 h, supernatants were removed and monolayers were over-
laid with DMEM containing 1 mM pyruvate, 2.5% FCS, 
3.75%  NaHCO3 and 0.6% agar. 2 days later cells were fixed 
with 75% methanol/25% acetic acid and stained with 0.25% 
crystal violet solution to count virus plaques.
Western blot analysis
For SDS-PAGE, cells or tissue were lysed using 8 M urea 
buffer containing 1% Triton, 0.1% SDS, 20 mM HEPES, 
8 mM EDTA, 2 mM EGTA, 50 mM sodium fluoride, 5 mM 
sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM 
TCEP and complete protease inhibitor cocktail (Roche). 
Western blot analysis was performed according to stand-
ard protocols. The following primary antibodies were used: 
β-actin (C4, Merck), α4 (K378/1, lab stock), α6 (K379, lab 
stock), β1(K43, lab stock), β5 (Abcam 3330), LMP2 (Abcam 
3328) and LMP7 (K63, lab stock). Secondary IRD680CW- 
or IRDye800CW-labeled antibodies were detected by the 
Odyssey CLx infrared imaging system (Li‐Cor Biosciences). 
Densitometric analysis was performed using Image Studio™ 
(Li‐Cor Biosciences) and values were normalized to internal 
loading controls.
Statistics
Statistical analysis of the data was performed in GraphPad 
Prism v7.00 and v8.00 for Windows (GraphPad Software). 
All data is plotted as individual points. If not indicated oth-
erwise, data summary are given as mean ± standard error 
of the mean (SEM). Data was first tested for normal distri-
bution using the D’Agostino-Pearson test. For non-normal 
distributed data a Mann–Whitney-test was used. Unpaired 
t-tests were used for two group comparisons of normal dis-
tributed data. If samples had unequal variances (determined 
by an F test), an unpaired t test with the Welch correction 
was used. For multiple group comparison, unequal variance 
versions of ANOVA (two-way ANOVA) were used. Sur-
vival was test for using a Gehan–reslow–Wilcoxon test. The 
significance threshold for all tests was set at the 0.05 level.
Results
Altered proteasome isoform composition 
in ip‑deficient  LMP7−/− mice mediates inflammatory 
perturbation of cardiac function in CV infection
A comparison of ip-deficient A/J-LMP7−/− mice with their 
wild-type controls revealed the pro-inflammatory role of the 
ip for the onset and manifestation of cardiac autoimmunity, 
with both processes being reversible in wild-type mice by 
treatment with ONX 0914 [12].  LMP7−/− mice resemble 
WT mice after ONX 0914 treatment with regard to the rela-
tive expression levels of the different ip subunits. They not 
only show a complete lack of LMP7, but also a profound 
reduction of Mecl-1 and lower LMP2 expression levels [40, 
42]. This defect of intact ip formation in  LMP7−/− mice can 
be attributed to the cooperative assembly of ip complexes 
[21]. Other than shown for PRR-activated immune cells 
after ip inhibition by ONX 0914, PRR-triggered cytokine 
responses, however, are not affected in  LMP7−/− immune 
cells [12, 43]. Based on the coherent phenotype found in 
both  LMP7−/− mice and in wild-type mice after ip inhibition 
in troponin I AM, we first asked whether the immunosup-
pressive effects seen in ONX 0914-treated A/J mice during 
CV infection can be phenocopied in A/J-LMP7−/− mice. If 
so, it would indicate that ip-dependent control of CV infec-
tion might be attributed to an altered adaptive immune 
response.
LMP7−/− mice and their age- and gender-matched 
 LMP7+/+ littermate controls were followed after infection 
with cardiotropic CV Nancy for 8 days, revealing no rel-
evant effect of LMP7 ablation on global health parameters, 
such as survival or body weight (Fig. 1b, c). Histological 
scoring of HE-stained heart tissue sections to evaluate 
myocardial necrosis and inflammation revealed profound 
myocarditis with similar scores in  LMP7−/− mice and their 
littermate wild-type controls (Fig. 1d, e). Correspondingly, 
a quantification of infiltrated immune cells in heart tissue 
by flow cytometry demonstrated an equivalent distribution 
of  CD11bhigh myeloid cells, with a slightly higher number 
of neutrophils in  LMP7−/− mice. The overall abundance of 
myeloid and lymphoid immune cells, however, was similar in 
both groups (Fig. 1f), confirming that the inflammatory heart 
tissue injury is not influenced by the impaired ip expression 
in  LMP7−/− mice. In addition to immune response-related 
effects, myocardial tissue injury observed 8 days after CV 
infection reflects the extent of viral cytotoxicity. To address 
the question of whether ablation of LMP7 in A/J mice 
affects the virus concentration during acute myocarditis, 
we quantified the virus titer in heart tissue by plaque assay 
and found an equivalent virus load of 5.4 × 105 ± 0.4 × 105 
pfu/g in  LMP7+/+ mice and 5.1 × 105 ± 0.2 × 105 pfu/g in 
 LMP7−/− mice (Fig. 1g).
To investigate whether ablation of LMP7 influences 
inflammation-triggered perturbation of cardiac function, 
as shown previously for ONX 0914-treated mice in viral 
myocarditis [2], we performed echocardiography prior to 
infection and during the acute phase of myocarditis. In line 
with our previous data [2, 40], the ejection fraction of the 
left ventricle was within the range of the values measured 
in naive mice prior to infection, regardless of LMP7 expres-
sion (Table 1). We found a reduced cardiac output, attributed 
to lower heart rate and an impaired stroke volume due to 
reduced left ventricular filling, both in  LMP7−/− and control 
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mice infected with CV (Table 1). Together, these data reflect 
that the inflammation-induced perturbation of the cardiac 
output, known to be mediated by the catalytic activity of the 
ip [2], can be similarly affected by the compensatory pro-
teasome activity present in ip-incompetent  LMP7−/− mice.
Since the modified proteasome activity, inherent in 
 LMP7−/− mice with ip dysfunction [10, 12], apparently neu-
tralizes the immunomodulatory potential of the ip that can be 
targeted in wild-type mice by inhibitors of this proteasome 
isoform, we questioned how other immune-related aspects 
with a specific functional requirement for intact ip proteoly-
sis are influenced in  LMP7−/− mice during CV infection. The 
peripheral blood count in CV infected mice showed a sig-
nificantly elevated level of leukocytes, and may be showing 
a trend towards higher neutrophil counts in  LMP7−/− mice 
(Fig. 2a), similar to findings in ONX 0914-treated A/J mice 
[2]. Spleen tissue, known to feature elevated levels of mye-
loid cells during CV infection, had a similar distribution 
of  CD11bhigh immune cells (Fig. 2b). Of note, the abun-
dance of inflammatory monocytes, which can be captured in 
spleen tissue of CV-infected mice by ip inhibition [2], was 
similar in both  LMP7−/− mice and their littermate controls 
(Fig. 2b), corresponding to the equal  CD11bhigh cell count 
in the heart during myocarditis in these groups (Fig. 1f). A 
Fig. 1  Phenotype of CV infection in ip-deficient  LMP7−/− A/J mice. 
a  LMP7+/+ (wild-type littermate controls, n = 9) and age and gender 
matched  LMP7−/− mice (n = 12) were infected with  104 pfu of CV 
Nancy and were analysed on day 8 postinfection (p.i.). b Survival and 
c body weight was monitored daily. d Formalin fixated and paraffin 
embedded heart tissue sections were stained using hematoxylin and 
eosin and myocarditis severity was assessed. e Representative micro-
graphs of haematoxylin and eosin stains are depicted for each group. 
f For further quantification of immune cell infiltration into the heart 
tissue, infiltrating immune cells per total heart were quantified by 
flow cytometry. g Virus concentration in heart tissue was assessed by 
plaque assay
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quantification of the lymphoid cells in spleen tissue showed 
a higher  CD4+ T cell count and elevated numbers for NK 
cells in infected  LMP7−/− mice, with no effect on B cells or 
 CD8+ T cells (Fig. 2c). Together, aside from neutrophils, the 
overall distribution of the immune cells and specifically that 
of  CD11b+ myeloid cells in infected mice differs between ip-
deficient  LMP7−/− mice (Fig. 2) and WT mice with inhibited 
ip activity [2].
Altered proteasome isoform composition 
in ip‑deficient  LMP7−/− mice allows ip‑mediated 
effects on myeloid immune cells
To differentiate the effects of ip-deficiency in 
 LMP7−/− mice from those of ONX 0914-treated WT mice 
in terms of the cellular composition of the main immune 
tissue compartments, we compared  CD11bhigh leuco-
cytes in bone marrow, spleen tissue and blood from naive 
 LMP7−/− mice with those of ONX 0914-treated mice. 
First, we asked how short term treatment with ONX 0914 
affects the proteasome composition in immune cell com-
partments. Figure 3 shows the Western blot-based analysis 
of proteasome subunits in bone marrow cells (BMC) and 
spleen, exemplarily performed for the LMP7/β5i, LMP2/
β1i, β1, β5, α4 and α6 subunit of ONX 0914-treated A/J 
WT mice 3 and 24 h after subcutaneous injection of the 
compound and in comparison to vehicle (Captisol) treat-
ment. A complete upward shift of the LMP7/β5i subunit, 
reflecting the irreversibly bound ONX 0914 in complex 
with this subunit, demonstrates that the accessibility 
of substrates to the active site of LMP7/β5i is blocked. 
LMP2/β1i is partially affected by ONX 0914 and after 
Table 1  Analysis of cardiac function in  LMP7−/− mice during acute 
CV myocarditis
Echocardiography was performed in  LMP7−/− mice and age- and 
gender-matched littermate controls prior to infection (baseline, day 0) 
and on day 8 post-infection (n = 9 per group). Data shown are mean 
values ± SEM and were analyzed using repeated measurements two-
way ANOVA, followed by Sidak’s multiple comparison test
EF: ejection fraction; bpm: beats per minute; Vol d/s: end-diastolic/-
systolic left ventricular volume; LVID-d/s: left ventricular inner 
dimension at diastole/systole
*Indicates significant differences in the respective treatment group at 
day 8 compared to this groups’ baseline measurement. There were no 
differences regarding to gene deficiency for LMP7
LMP7+/+ (WT) LMP7−/−
Baseline Day 8 Baseline Day 8
Heart rate (bpm) 402 ± 23 363 ± 33 429 ± 17 368 ± 20
Trace EF (%) 57.8 ± 2.9 60.6 ± 1.1 57.0 ± 2.3 62.9 ± 2.4
Cardiac output 
(mL/min)
8.4 ± 0.6 6.3 ± 1.2 9.8 ± 0.6 6.0 ± 0.7*
Stroke volume (µL) 20.9 ± 1.0 16.5 ± 2.0 22.9 ± 0.8 16.1 ± 1.3*
Vol d (µL) 36.2 ± 1.0 27.2 ± 3.2* 40.3 ± 1.0 25.8 ± 2.2*
Vol s (µL) 15.3 ± 1.2 10.7 ± 1.2* 17.4 ± 1.2 9.7 ± 1.2*,§
LVID-d (mm) 3.6 ± 0.1 3.0 ± 0.2* 3.7 ± 0.1 3.0 ± 0.1*
LVID-s (mm) 2.5 ± 0.1 2.1 ± 0.1* 2.5 ± 0.1 2.0 ± 0.1*
Fig. 2  Peripheral immune cell composition in  LMP7−/− A/J mice 
during CV infection. a At day 8 p.i., blood was drawn for a peripheral 
blood count. b, c At the same time point, spleen tissue was homog-
enized and single cell suspensions were subjected to immune cell 
quantification by flow cytometry (n = 6  LMP7+/+ and n = 9  LMP7−/− 
mice)
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3 h β5 is slightly inhibited, but recovers full activity by 
24 h. Importantly, other than what has been reported for 
 LMP7−/− mice [40, 43], using this set-up, ONX 0914 had 
no effect on the overall proteasome levels or on catalytic 
subunits of the standard proteasome, as indicated by simi-
lar expression levels for α4 and α6, as well as β1 and β5, 
respectively.
We then analyzed  CD11bhigh immune cells from age- and 
gender matched naive  LMP7−/− and  LMP7+/+ A/J mice, as 
well as ONX 0914 and Captisol-treated A/J WT mice, by 
flow cytometry. The results depicted in Fig. 4a show that 
the myeloid immune cell composition is unaffected in naive 
 LMP7−/− mice, with equivalent counts of monocytes, mac-
rophages and dendritic cells in bone marrow, spleen and 
blood when compared to their WT controls. In contrast, inhi-
bition of the ip by ONX 0914 in naive A/J WT mice reduced 
the abundance of inflammatory monocytes, showing the 
most prominent reduction in bone marrow (Fig. 4b). From 
these experiments, we conclude that the pathophysiological 
effects controlled by inflammatory monocytes, which are 
crucial in CV myocarditis [35], might differ a great deal in 
ip-deficient  LMP7−/− and WT mice in which ip proteolysis 
has been inhibited by ONX 0914. In  LMP7−/− mice, the 
myeloid immune cell counts resemble those of WT mice, 
whereas ONX 0914 exerts distinct effects.
Immunoproteasome inhibition by ONX 0914 
during the second wave of CV infection fails 
to improve the cardiac output
Others and we have demonstrated the critical role of inflam-
matory monocytes as a source of pro-inflammatory and 
pro-fibrotic cytokines in the pathogenesis of myocarditis 
and its sequela, inflammatory cardiomyopathy [33, 35]. 
However, based on the different influences of ip depletion 
in  LMP7−/− mice and ip inhibition by ONX 0914 on CV 
myocarditis, it is unclear whether inhibitors of the ip, such 
as ONX 0914, would be effective in a clinically relevant 
setting to dampen adverse inflammatory responses during 
acute viral myocarditis. The established pro-inflammatory 
role of the ip leading to cardiac dysfunction in CV-infected 
A/J mice [2] prompted us to ask how ONX 0914 treatment, 
initiated after the first inflammatory wave seen 2–3 days 
after viral infection, can influence cardiac performance and 
the severity of viral myocarditis.
To set up an appropriate experimental ONX 0914 treat-
ment protocol for the second inflammatory wave with acute 
myocarditis in CV infected A/J mice, we considered the fol-
lowing aspects. We wished to initiate ONX 0914 treatment 
as soon as the primary inflammatory response due to affec-
tion of pancreas and liver tissue has been established, based 
on our previous experience with this model. As indicated 
recently for other laboratory mouse strains, CV infection of 
A/J WT mice triggers a hypoglycemic state with a prominent 
dip in serum glucose levels early after infection (Fig. 5a), in 
parallel with the peak systemic cytokine response around 
day three/four in A/J mice [2]. From this stage onward, the 
virus titer in the liver tissue drops, reaching a complete 
lack of infectious viral particles by 6 days after infection 
(Fig. 5b). The virus titer in heart tissue, however, increases 
at this point in time (Fig. 5c), reflecting active viral rep-
lication in cardiac tissue. Serum glucose levels serve as a 
surrogate parameter of the systemic inflammatory condition 
during infection and they rise again after 6 days (Fig. 5a). 
Based on these temporal aspects of established systemic 
inflammatory responses, 3 days after infection prior to 
virus replication in cardiac tissue, we initiated ONX 0914 
in CV-infected A/J mice on day 3 and followed mice up 
to 8 days (Fig. 6a), where inflammatory responses peak in 
the heart. The overall weight loss that we observed during 
CV infection was not influenced by ONX 0914 treatment 
(Fig. 6b), with no CV-induced mortality, regardless of the 
treatment group (data not shown). Histological staining of 
cardiac sections revealed middle-grade necrosis/inflamma-
tion in both the ONX 0914 and Captisol-treated groups, with 
no indication of an anti-inflammatory response under the 
Fig. 3  Proteasome inhibition and effects on the expression levels of 
proteasome subunits by short time ONX 0914 treatment. A/J mice 
were treated with the vehicle  Captisol® or 10  mg/kg BW of the ip 
inhibitor ONX 0914. After 3 and 24  h, bone marrow cells (BMC) 
and spleen tissue were removed and protein lysates were subjected 
to Western blot analysis (n = 1 per time point and treatment). Protea-
some composition in each sample was analysed using primary anti-
bodies against the α4 and α6 subunits expressed in all proteasome 
isoforms and the proteolytically active immunoproteasome subunits 
LMP7 and LMP2 and their respective standard proteasome coun-
terparts β5 and β1. The additional upwards shifted bands indicate a 
binding and inactivation by ONX 0914 of the respective proteasomal 
subunits. Actin was used to indicate protein loading
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influence of ONX 0914 (Fig. 6c, d). This result was corrobo-
rated by quantitative analysis of immune cells in heart tis-
sue by flow cytometry. The total number of  CD45+ immune 
cells was equivalent in both treatment groups (Fig. 6e), with 
 CD11bhigh myeloid cells being the most abundant immune 
cells in the inflamed heart. Infiltration of inflammatory 
monocytes and neutrophils, but also that of T and B cells 
was not influenced by ONX 0914 (Fig. 6f). Similarly, the 
production of chemotactic cytokines as well as the produc-
tion of pro-inflammatory cytokines, such as IFN-γ, IL-1β, 
Fig. 4  Immune cell phenotyping in naive ip-deficient  LMP7−/− A/J 
mice and ONX 0914 treated A/J mice. a Immune cell composition of 
 LMP7+/+ and age and gender matched  LMP7−/− littermates (n = 6 per 
group) was analysed in the bone marrow, spleen and peripheral blood 
by flow cytometry. Bone marrow was taken from 2 femurs and 2 tib-
ias of each mouse and total cells were quantified. b Similarly, in A/J 
mice treated with vehicle (n = 4) or 10 mg/kg BW ONX 0914 (n = 4), 
immune cell compartments were harvested 18 h later. Immune cells 
were quantified by flow cytometry in the bone marrow of 2 femurs 
and 2 tibias, spleen and peripheral blood. The variability between the 
absolute immune cell abundancies, e.g., for  Ly6Chigh monocytes in 
bone marrow from WT mice in a and sham-treated WT mice in b, 
may be attributed due to heterogenous experimental conditions and 
slightly diverse counting approaches of the two experimenters for a 
and b. A direct comparison between the absolute cell counts in (a) 
and (b) is not valid
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IL-6 and TNF-α, was not affected by ONX 0914 treatment 
(Fig. 6h). The virus concentration as reflected by the viral 
genome count and viral particle load in heart tissue after 
8 days, revealed a higher CV content in the ONX 0914 group 
(Fig. 6i, j).
Based on previous reports on re-shaped T cell differen-
tiation with altered expression levels of inhibitory immune 
checkpoint molecules [12, 49], we then asked whether ONX 
0914 treatment might influence the T cell response in viral 
myocarditis. We quantified the mRNA expression levels of 
the early activation antigen CD69, together with IL-2 and 
IFN-γ, for both  CD8+ and  CD4+ T cell activation, granzyme 
A and perforin 1 as effector molecules of a  CD8+ T cell 
response, as well as IL17, CD25 and FoxP3 levels for  CD4+ 
T cell differentiation, in addition to the immune checkpoint 
molecule PD-1. In infected heart tissue, IL-2 and IFN-γ 
levels, produced by both  CD8+ and  CD4+ T cells, were 
increased regardless of ONX 0914 treatment, a finding cor-
responding to equally elevated expression of CD69 and PD-1 
(Fig. 7a). IL-17 production was not upregulated in infected 
heart tissue, which argues against a substantial infiltration 
of Th17 cells during viral myocarditis of A/J mice. The ele-
vated expression levels of CD25 and FoxP3 in heart tissue 
indicated an infiltration of regulatory T cells, with no effect 
of ONX 0914 treatment. The quantification of granzyme 
A and perforin 1, both effector molecules of  CD8+ T cells, 
revealed lower expression levels in ONX 0914-treated mice 
(Fig. 7a). This, in line with our previous study [2], indicates 
fewer active  CD8+ T cells, a population making only a minor 
contribution to the pool of invading immune cells. Overall, 
our data show that ONX 0914 exerts no major effects on T 
cell responses in the infected heart. Since the heart tissue, 
as an effector organ of the adaptive immune response, might 
not reflect all systemic effects potentially exercised by ONX 
0914, we also profiled  CD8+ and  CD4+ T cell activation in 
spleen, a secondary lymphoid organ (Fig. 7b). Splenic T 
cells had a lower activation status in comparison to the cells 
in heart tissue, as reflected by unaltered expression of CD69, 
IL-2, IFN-γ and granzyme A in infected mice, regardless of 
ONX 0914 treatment. Importantly, in the ONX 0914-treated 
group, mRNA expression profiling revealed a marked 
increase of FoxP3 and higher CD25 levels, indicative of an 
elevated presence of regulatory  CD4+ T cells in comparison 
to the vehicle group. Together with elevated PD-1 levels, an 
inhibitory immune checkpoint molecule, these data indicate 
that ONX 0914 steers the adaptive  CD4+ T cell response 
towards an immune suppressive activity, which leads to less 
effective control of the virus in heart tissue upon treatment 
with ONX-0914.
Nevertheless, despite the adverse effects of ONX 0914 
on virus control, the inflammatory heart tissue damage dur-
ing acute myocarditis was not substantially affected when-
ever blockade of ip activity was postponed to a time point 
after systemic inflammation was established. Importantly, 
the anti-inflammatory influence of ONX 0914 treatment 
observed when treatment was initiated prior to infection [2] 
vanished completely. Similar to our analysis of viral myo-
carditis in  LMP7−/− mice, echocardiography was performed 
to determine whether ONX 0914 treatment, applied during 
the second wave of infection, influences cardiac function. 
CV infection in A/J mice resulted in a significant drop of the 
cardiac output, mainly attributed to impaired left ventricu-
lar filling (Vol d), which was not influenced by ONX 0914 
treatment (Table 2). The elevation of the LVEF in vehicle-
treated mice during viral myocarditis, which was absent in 
the infected ONX 0914 group and had not been observed in 
any of our previous studies [2, 40], had virtually no effect on 
the cardiac output. We conclude that ONX 0914-mediated ip 
inhibition, initiated after the primary inflammatory response 
in CV infection has been established, cannot counteract the 
inflammation-triggered impairment of the cardiac output.
Discussion
In a recent study, we demonstrated that, in contrast to the 
effects seen in CV-infected C57BL/6 and NMRI mice [2, 
40], the ip inhibitor ONX 0914 protects A/J mice from 
developing CV myocarditis. In A/J mice, where the severe 
CV-triggered pathology is primarily attributed to a sepsis-
like cytokine storm and distributive shock condition, ip 
activity is on the whole detrimental [2]. Unlike C57BL/6 
mice [28], A/J mice can also be used as a model organ-
ism to investigate troponin I-directed cardiac autoimmunity 
[20]. AM is known to be triggered by viral infection [46] or 
by therapy with immune checkpoint inhibitors (ICI) target-
ing, e.g., the PD-1/PD-1L pathway [25], with ICI-related 
Fig. 5  Biphasic course of CV infection in A/J mice. A/J mice were 
infected with CV Nancy. Mice were analysed on day 3/4 and day 6 
after infection for a blood glucose levels using a clinically approved 
glucose meter and virus concentration in b liver and c heart tissue by 
plaque assay
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Fig. 6  Impact of ONX 0914 treatment on viral myocarditis after sys-
temic inflammation has been established. a Age and gender matched 
A/J mice were infected with CV Nancy. Starting on day 3, CV 
infected mice were either treated with the vehicle  Captisol® or with 
10 mg/kg BW ONX 0914 daily (n = 10 per group) and mice were ana-
lysed on day 8. b Body weight was monitored daily. c, d Formalin 
fixated and paraffin embedded heart tissue sections were stained with 
hematoxylin and eosin and myocarditis severity was assessed. Rep-
resentative micrographs of the hematoxylin and eosin stained heart 
tissue sections are depicted d. e, f Immune cell infiltration into the 
heart was quantified by flow cytometry. Chemotactic g and h pro-
inflammatory cytokine mRNA expression in cardiac tissue on day 8 
after infection, as determined by qPCR in both groups (n = 10) and 
normalized to vehicle (n = 5) or ONX 0914-treated control groups 
(n = 6). Virus concentration was quantified by plaque assay (I) 
and viral genome was analyzed by qPCR j. Data is summarized as 
mean ± SEM
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myocarditis being a severe, if rare, side effect in cancer 
immunotherapy [12]. Similar to viral myocarditis, in AM 
of A/J mice, the ip stimulates the production of chemot-
actic and pro-inflammatory cytokines, the later govern-
ing  CD4+ T cell differentiation into Th17 and Th1 cells in 
autoimmune heart disease [39] and cumulating in cardiac 
tissue damage and dysfunction [12]. Based on these find-
ings, we set up this study, aiming to obtain a deeper insight 
into the immune pathways that contribute to the adverse 
effects achieved by ip-mediated proteolysis in CV-infected 
A/J mice and simultaneously question the therapeutic util-
ity of ip inhibitors for severe viral myocarditis. Altogether, 
our findings demonstrate that the therapeutic efficacy of ip 
inhibitors for CV-triggered myocarditis in A/J mice relies on 
their immunomodulatory effects on the systemic inflamma-
tory response reaction.
Several aspects initially prompted us to investi-
gate CV myocarditis in A/J-LMP7−/− mice. From 
the mouse model of TnI-induced AM, we knew that 
the phenotype found in ip-deficient mice, seen for 
 LMP2−/− and  LMP2−/−/LMP7−/−/Mecl-1−/− mice in addi-
tion to  LMP7−/− mice, has the same mitigated inflamma-
tion during AM, and this was also observed in mice treated 
with the ip inhibitor ONX 0914 [12]. Contrary to the effects 
attributed to ip inhibition in this model, PRR-triggered pro-
inflammatory cytokine responses, however, are not substan-
tially affected by genetic ablation of ip subunits [11, 15, 37]. 
These divergent results, obtained with TLR-activated mac-
rophages or monocytes from  LMP7−/− mice in comparison 
to ONX 0914-treated cells from WT mice, indicate that the 
elevated expression of the standard proteasome, seen, e.g., 
in spleen tissue of  LMP7−/− mice [12], triggers similar pro-
inflammatory cytokine responses, as the ones mediated by ip 
proteolysis in WT mice. Other than that, a short-term ONX 
0914 treatment, as shown here, has no relevant influence on 
the level of the standard proteasome after 24 h in cells from 
spleen or bone marrow. The reduction of the cardiac output 
in CV-infected  LMP7−/− mice, which is mainly attributed to 
lower ventricular filling and does not involve a deterioration 
of the systolic function of the left ventricle, is not altered in 
comparison to WT controls. Diastolic filling in CV-infected 
mice reflects the systemic pro-inflammatory reaction, lead-
ing to lower peripheral resistance of the vasculature [2, 13, 
32]. The reduced cardiac output that we found in both CV-
infected  LMP7−/− mice and littermate WT controls implies 
similar cytokine responses triggered by CV infection in 
both hosts. Moreover, this finding also implicates that the 
improved cardiac filling, which we reported earlier for CV-
infected A/J mice under the influence of ONX 0914 [2], is 
at least partially attributed to a suppression of the systemic 
cytokine response early upon infection, found in infected 
animals with blocked ip activity and lack of compensatory 
standard proteasome formation [40].
Supportive data for the differential myeloid-cell derived 
inflammatory immune response in WT mice with ONX 
0914-blocked ip activity in comparison to genetic ablation 
of ip subunits in  LMP7−/− mice comes from our finding that 
myeloid immune cell counts are heterogeneously affected. 
The prominent ONX 0914-mediated neutrophilia [2, 38], 
which is due to promoted egress of this cell population 
from the bone marrow niche [2], is less well developed, if 
it is present at all, in  LMP7−/− mice. Other than by ONX 
0914 treatment, where consistent with findings of this study, 
reduced human monocyte counts emerge [6], monocyte 
counts in infected, but also in naive  LMP7−/− mice, show 
no differences relative to those measured in WT mice. From 
these experiments, we conclude that the pathophysiological 
Fig. 7  Impact of ONX 0914 treatment on T cell responses. Age 
and gender matched A/J mice were infected with CV Nancy. Start-
ing on day 3, CV infected mice were either treated with the vehi-
cle  Captisol® or with 10  mg/kg BW ONX 0914 daily (n = 10 per 
group) and mice were analysed on day 8. The data reflect car-
diac a and splenic b mRNA expression levels, as determined by 
qPCR in each group (n = 10) and normalized to vehicle ( = 5) and 
nONX 0914-treated control groups (n = 6). Data is summarized as 
mean ± SEM
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effects controlled by inflammatory monocytes, which are 
crucial in CV myocarditis [35], might differ a great deal 
between ip-deficient  LMP7−/− mice and WT mice, where ip 
proteolysis is inhibited by ONX 0914 only for a short time. 
In  LMP7−/− mice, the myeloid immune cell counts resem-
ble those of WT mice, whereas ONX 0914 exerts specific 
effects, indicating that the ip controls cellular processes, 
such as survival and/or proliferation of inflammatory mono-
cytes [6]. In ip-deficient mice with inborne defects of LMP7, 
these effects are not observed, suggesting other genes are 
compensating for the missing gene products. Such biological 
compensation, attributed to increased standard proteasome 
expression in  LMP7−/− mice, apparently camouflages the 
contribution of ip activity to the pathology observed early in 
CV infection. Nevertheless, cells after long-term treatment 
with ONX 0914, such as for a 4 week period in AM, exert 
changes of the proteasome subunit expression profile simi-
lar to those seen in  LMP7−/− mice [12]. Such adaption by 
the standard proteasome counterpart of the ip explains why 
ONX 0914-mediated effects, such as on myeloid cell abun-
dance, can vanish after such a prolonged treatment protocol.
Other than has been shown for the systemic inflam-
matory response, the impact of ip proteolysis on  CD4+ T 
cell activation and differentiation towards Th17 lympho-
cytes with less regulatory T cells, as well as suppression 
of inhibitory immune checkpoint molecules, such as PD-1, 
appears to be the same for  LMP7−/− mice and ip-inhibitor 
treated animals [7, 9, 12, 37]. In fact, this study confirmed 
the role of ip inhibitors for steering  CD4+ T cell differen-
tiation towards a suppressive phenotype with more regula-
tory T cells and higher expression of PD-1 in spleen tissue, 
also during viral myocarditis. The finding that myocardial 
inflammation remains unaffected in both  LMP7−/− and ONX 
0914-treated mice (days 3–8) indicates that those adap-
tive immune responses operative in troponin I AM, most 
likely do not substantially contribute to the manifestation of 
acute CV myocarditis in A/J mice. On the other hand, the 
immunosuppressive activity of ONX 0914 on pro-inflam-
matory  CD4+ T cell immunity might partially explain why 
the virus concentration was increased in heart tissue under 
the influence of ONX 0914 (days 3–8). In troponin I AM, 
heart-directed autoimmunity in A/J mice results in reduced 
systolic function of the left ventricle, with mitigated inflam-
mation in  LMP7−/− mice leading to improved cardiac func-
tion [12]. However, in viral myocarditis, others and we found 
no decrease in the contractile performance of the heart, as 
would be reflected by reduced LVEF, irrespective of the 
genetic background of the laboratory mouse strains tested 
[2, 34, 35, 40]. Therefore, even if a beneficial effect, such as 
ablation of LMP7, were to be expected, a biologically rel-
evant improvement of the LVEF in CV-infected mice would 
be unlikely. Altogether, our experiments with CV infected 
 LMP7−/− (A/J) mice indicate that the pro-inflammatory 
action achieved by ip proteolysis is compensated for by an 
altered proteasome isoform pattern [12, 48] that virtually 
balances the biological effects seen in infected WT mice.
The anti-inflammatory capacity of ip inhibitors is 
remarkable in troponin I AM [12] and, similar to obser-
vations in experimental autoimmune encephalomyeli-
tis (EAM) [9], also the progression of the disease can 
be ameliorated by ONX 0914, even after autoimmunity 
has been established in these models. In contrast to these 
reports on autoimmunity, where ONX 0914 is protective 
following both prophylactic and therapeutic approaches, 
in this study, we demonstrate that delay of the initiation 
of ONX 0914 treatment to a time point when systemic 
Table 2  Analysis of cardiac 
function in A/J mice after ONX 
0914 treatment during acute CV 
myocarditis
ONX 0914 (10 mg/kg BW) was initiated in A/J mice 3 days after to infection (n = 10). Echocardiography 
was performed prior to infection (baseline, day 0) and on day 8 post-infection. Age- and gender-matched 
vehicle-treated mice served as controls (n = 10 vehicle). Data shown are mean values ± SEM and were ana-
lyzed using repeated measurements two-way ANOVA, followed by Sidak’s multiple comparison test
EF: ejection fraction; bpm: beats per minute; Vol d/s: end-diastolic/-systolic left ventricular volume; LVID-
d/s: left ventricular inner dimension at diastole/systole
*Indicates significant differences in the respective treatment group at day 8 compared to this groups’ base-
line measurement. § indicates significant differences regarding to ONX 0914 treatment after infection
Vehicle ONX 0914
Baseline Day 8 Baseline Day 8
Heart rate (bpm) 401 ± 11 354 ± 15 410 ± 10 379 ± 14
Trace EF (%) 48.6 ± 1.6 57.2 ± 3.3 47.6 ± 1.0 46.1 ± 3.1§
Cardiac output (mL/min) 8.9 ± 0.4 6.2 ± 0.3* 8.2 ± 0.3 5.9 ± 0.5*
Stroke volume (µL) 22.2 ± 1.0 17.4 ± 0.7* 20.0 ± 0.6 15.5 ± 1.3*
Vol d (µL) 45.6 ± 1.2 31.4 ± 2.1* 42.1 ± 0.8 33.5 ± 1.6*
Vol s (µL) 23.4 ± 0.8 14.0 ± 1.8* 22.1 ± 0.6 18.1 ± 1.3*,§
LVID-d (mm) 3.7 ± 0.1 3.3 ± 0.1* 3.7 ± 0.1 3.2 ± 0.1*
LVID-s (mm) 2.8 ± 0.1 2.4 ± 0.1* 2.8 ± 0.1 2.4 ± 0.1*
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inflammatory responses in CV infected A/J mice emerge 
prior to cardiac injury, has no beneficial effect on viral 
myocarditis. In fact, reminiscent of previous reports in 
NMRI [40] and C57BL/6 mice [2], we found that ONX 
0914 treatment apparently interfered with host response 
pathways, which limit the virus concentration in heart 
tissue. In addition to altered  CD4+ T cell immunity, this 
might be attributed to a lack of ip selectivity for ONX 
0914 in inflamed heart tissue, with the compound leading 
to substantial inhibition of the standard cardiac proteasome 
subunit β5 at this stage. Regarding the anti-inflammatory 
role of ONX 0914, we confirmed earlier that ONX 0914 
efficiently blocked ip function also at advanced stages of 
CV infection, such as in spleen tissue [40], arguing against 
any loss of inhibitory capacity by ONX 0914 in immune 
cells with constitutive ip expression. Thus, the anti-inflam-
matory action of ip inhibitors must take place prior to the 
manifestation of the first inflammatory wave in A/J mice 
to exert a biologically relevant effect on CV infection. 
During CV myocarditis, the cardiac output, together with 
the diastolic filling, were not influenced by ONX 0914 
applied between 3 and 7 days after infection. In contrast, 
ONX 0914-mediated inhibition of systemic inflammation 
in CV infection, whenever the compound was adminis-
tered prior to infection, resulted in higher ventricular fill-
ing and improved cardiac output [2]. Based on this, we 
hypothesize that, in general, mainly the systemic inflam-
matory condition and the thereby altered vascular tonus 
contribute to the reduced cardiac output, seen after CV 
infection, whereas cardiac injury, if it has any influence at 
all, it is a minor one. Further support for the fact that the 
systemic inflammatory response is the main determinant 
for the reduced cardiac output in infected mice comes from 
another study. Infection of mice with a genetically engi-
neered CV, exerting a comparatively mild first inflamma-
tory wave, yet targeting the heart, develop no functional 
deterioration of the heart despite the emergence of viral 
cytotoxicity and inflammatory responses in the heart [44].
In conclusion, this study demonstrates that the beneficial 
effects to mitigate CV-triggered myocarditis in A/J mice 
due to inhibition of the ip rely on their immunomodulatory 
effects on the systemic inflammatory response reaction. To 
mitigate cardiac inflammation in viral myocarditis, blockade 
of the ip needs to be accomplished by the inhibitory com-
pound, prior to when the cytokine-triggered global inflam-
matory response promotes cardiac inflammatory injury. 
Data from other laboratory strains, such as C57BL/6 and 
NMRI mice, obtained while undergoing CV myocarditis, 
showed that treatment with ONX 0914 either had no effect 
or it resulted in exacerbated myocardial inflammation [2, 
40]. Together with these results, the need for targeting the 
systemic inflammatory response prior to the onset of myo-
cardial injury to achieve mitigated viral myocarditis in A/J 
mice hampers the utility of ip inhibitors for acute viral heart 
disease.
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